Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Shares Outstanding (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Shares Outstanding for 7 consecutive years, with $40.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding changed 0.29% year-over-year to $40.7 million, compared with a TTM value of $40.7 million through Dec 2025, changed 0.29%, and an annual FY2025 reading of $40.7 million, changed 0.29% over the prior year.
  • Shares Outstanding was $40.7 million for Q4 2025 at Keros Therapeutics, roughly flat from $40.6 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $40.7 million in Q4 2025 and bottomed at $23.3 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $31.6 million, with a median of $29.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding skyrocketed 833.97% in 2021, then grew 0.29% in 2025.
  • Year by year, Shares Outstanding stood at $24.0 million in 2021, then increased by 14.88% to $27.5 million in 2022, then grew by 15.6% to $31.8 million in 2023, then increased by 27.37% to $40.6 million in 2024, then rose by 0.29% to $40.7 million in 2025.
  • Business Quant data shows Shares Outstanding for KROS at $40.7 million in Q4 2025, $40.6 million in Q3 2025, and $40.6 million in Q2 2025.